Evidence map›Paper›PMID 35157765›Full record

ArticleBlood2022

Defects in mucosal immunity and nasopharyngeal dysbiosis in HSC-transplanted SCID patients with IL2RG/JAK3 deficiency.

Pedro Goncalves, Jean-Marc Doisne, Toshiki Eri, Bruno Charbit, Vincent Bondet, Celine Posseme, Alba Llibre, Armanda Casrouge, Christelle Lenoir, Bénédicte Neven and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Pedro GoncalvesInstitut Pasteur, Université de Paris Cité, Inserm U1223, Innate Immunity Unit, Paris, France.ORCID 0000-0002-4127-1152
Jean-Marc DoisneInstitut Pasteur, Université de Paris Cité, Inserm U1223, Innate Immunity Unit, Paris, France.ORCID 0000-0001-6714-1308
Toshiki EriInstitut Pasteur, Université de Paris Cité, Inserm U1223, Innate Immunity Unit, Paris, France.ORCID 0000-0001-6233-6966
Bruno CharbitInstitut Pasteur, Université de Paris Cité, Center for Translational Science, Paris, France.ORCID 0000-0002-5478-482X
Vincent BondetInstitut Pasteur, Université de Paris Cité, Translational Immunology Unit, Paris, France.ORCID 0000-0002-6534-0984
Celine PossemeInstitut Pasteur, Université de Paris Cité, Translational Immunology Unit, Paris, France.ORCID 0000-0003-4182-6442
Alba LlibreInstitut Pasteur, Université de Paris Cité, Translational Immunology Unit, Paris, France.
Armanda CasrougeInstitut Pasteur, Université de Paris Cité, Inserm U1223, Innate Immunity Unit, Paris, France.
Christelle LenoirInserm Unité Mixte de Recherche 1163, Paris, France.
Bénédicte NevenInserm Unité Mixte de Recherche 1163, Paris, France.
Darragh DuffyInstitut Pasteur, Université de Paris Cité, Translational Immunology Unit, Paris, France.
Alain FischerInserm Unité Mixte de Recherche 1163, Paris, France.
James P Di SantoInstitut Pasteur, Université de Paris Cité, Inserm U1223, Innate Immunity Unit, Paris, France.ORCID 0000-0002-7146-1862
Milieu Intérieur Consortium
Inserm · FRInstitut Pasteur · FRDélégation Paris 5 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Both innate and adaptive lymphocytes have critical roles in mucosal defense that contain commensal microbial communities and protect against pathogen invasion. Here we characterize mucosal immunity in patients with severe combined immunodeficiency (SCID) receiving hematopoietic stem cell transplantation (HSCT) with or without myeloablation. We confirmed that pretransplant conditioning had an impact on innate (natural killer and innate lymphoid cells) and adaptive (B and T cells) lymphocyte reconstitution in these patients with SCID and now show that this further extends to generation of T helper 2 and type 2 cytotoxic T cells. Using an integrated approach to assess nasopharyngeal immunity, we identified a local mucosal defect in type 2 cytokines, mucus production, and a selective local immunoglobulin A (IgA) deficiency in HSCT-treated SCID patients with genetic defects in IL2RG/GC or JAK3. These patients have a reduction in IgA-coated nasopharyngeal bacteria and exhibit microbial dysbiosis with increased pathobiont carriage. Interestingly, intravenous immunoglobulin replacement therapy can partially normalize nasopharyngeal immunoglobulin profiles and restore microbial communities in GC/JAK3 patients. Together, our results suggest a potential nonredundant role for type 2 immunity and/or of local IgA antibody production in the maintenance of nasopharyngeal microbial homeostasis and mucosal barrier function.

Indexed as

Severe Combined ImmunodeficiencyDysbiosisHumansImmunity, InnateImmunity, MucosalImmunoglobulin AInterleukin Receptor Common gamma SubunitJanus Kinase 3LymphocytesIL2RG protein, humanImmunoglobulin AInterleukin Receptor Common gamma SubunitJAK3 protein, humanJanus Kinase 3

Identifiers

PMID35157765
PMCPMC11022929
OpenAlexW4213389526

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.